6-bromohexanoylbromide

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 6-bromohexanoylbromide
• 英文别名: Brom-caproylbromid；6-bromohexanoyl bromide
• 化学式: C₆H₁₀Br₂O
• 分子量: 257.953
• InChiKey: NOPKNBDBHMWPEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-甲氧基色胺 、 6-bromohexanoylbromide 在 三乙胺 作用下， 以 氯仿 为溶剂， 反应 1.0h， 以82%的产率得到6-Bromo-hexanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide
  参考文献：
  名称：

  Henin; Noe; Laronze, Pharmaceutical Sciences, 1997, vol. 3, # 5-6, p. 289 - 290

  摘要：

  DOI：

文献信息

• [EN] PROCESS AND METHOD FOR THE EFFICIENT PREPARATION OF FULLERYNES<br/>[FR] PROCÉDÉ ET MÉTHODE POUR LA PRÉPARATION EFFICACE DE FULLERYNES
  申请人：UNIV AKRON

  公开号：WO2012005762A1

  公开（公告）日：2012-01-12

  The preparation of novel fullerynes which are fullerenes (e.g. C60, C70, C80, etc.) that contain one or more alkyne functionalities and may contain additional functional groups such as hydroxyls, halogens, esters, haloesters, phenyl, oligo(ethylene glycol)s, perfluorinated alkyl chains, and the like. Two desired preparation routes are disclosed. The first one is the Fischer esterification in desired solvents using a special designed reactor in contrast to the heretofore initial Steglich reaction that results in side reactions and low yields. The second one uses acetylide Grignard reagents that have reduced nucleophilicity and higher stability in contrast to the use of heretofore initial lithium organyls or other Grignard reagents that would add to C60 with possible multi-additions in an uncontrollable manner.

  制备新型富勒烯，该富勒烯（例如C60，C70，C80等）含有一个或多个炔基官能团，并可能含有额外的官能团，例如羟基，卤素，酯，卤代酯，苯基，寡聚（乙二醇）和全氟烷基等。文中介绍了两种所需的制备路线。第一种是在特定溶剂中使用特殊设计的反应器进行Fischer酯化反应，与此前的Steglich反应相比，可以避免副反应和低收率。第二种方法使用乙炔基格氏试剂，其亲核性降低且稳定性更高，相比于此前使用的锂有机化合物或其他格氏试剂，可以避免多次无法控制的加成反应。
• Novel amide compounds and medications containing the same
  申请人：Shibuya Kimiyuki

  公开号：US20050131002A1

  公开（公告）日：2005-06-16

  The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.

  本发明提供了一种具有ACAT抑制活性的新化合物。本发明涉及由式(I)表示的化合物，其中表示一种可选取代的二价残基，例如苯，吡啶，环己烷或萘，或者一个基团，Het表示一种5-至8-成员的取代或未取代的杂环基团，其中至少包含从氮原子，氧原子和硫原子中选取的一种杂原子，例如单环基团，多环基团或融合环的基团，X表示-NH-，氧原子或硫原子，Y表示-NR4-，氧原子，硫原子，亚砜或磺酰基，Z表示单键或-NR5-，R4表示氢原子，低碳基，芳基或可选取代的硅烷低碳基，R5表示氢原子，低碳基，芳基或可选取代的硅烷低碳基，n为1到15的整数，或其盐或溶剂，以及含有这些化合物中至少一种的药物组合物。
• Novel amide compounds and medications containing the same technical field
  申请人：Shibuya Kimiyuki

  公开号：US20050131001A1

  公开（公告）日：2005-06-16

  The present invention provides to a novel compound having an ACAT inhibiting activity. The present invention relates to compounds represented by formula (I) wherein represents an optionally substituted divalent residue such as benzene, pyridine, cyclohexane or naphthalene, or a group, Het represents a 5- to 8-membered, substituted or unsubstituted heterocyclic group containing at least one heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, such as a monocyclic group, a polycyclic group or a group of a fused ring, X represents —NH—, an oxygen atom or a sulfur atom, Y represents —NR 4 —, an oxygen atom, a sulfur atom, a sulfoxide or a sulfone, Z represents a single bond or —NR 5 —, R 4 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, R 5 represents a hydrogen atom, a lower alkyl group, an aryl group or an optionally substituted silyl lower alkyl group, and n is an integer of from 1 to 15, or salts or solvates thereof, and a pharmaceutical composition containing at least one of these compounds.

  本发明提供了一种具有ACAT抑制活性的新化合物。本发明涉及由式(I)表示的化合物，其中表示可选取代的二价残基，例如苯，吡啶，环己烷或萘，或基团，Het表示包含至少一种异原子（从氮原子，氧原子和硫原子中选择）的5-至8-成员取代或未取代的杂环基团，例如单环基团，多环基团或融合环基团，X表示-NH-，氧原子或硫原子，Y表示-NR4-，氧原子，硫原子，亚砜或磺酰基，Z表示单键或-NR5-，R4表示氢原子，低碳基，芳基或可选取代的硅基低碳基，R5表示氢原子，低碳基，芳基或可选取代的硅基低碳基，n为1至15的整数，或其盐或溶剂，以及含有这些化合物中至少一种的药物组合物。
• Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
  申请人：NIHON MEDI-PHYSICS CO., LTD.

  公开号：EP0565930A1

  公开（公告）日：1993-10-20

  There is disclosed a compound of the formula: The compound (1) is a bifunctional complexing agent and forms a metal complex with a metal ion and a biologically functional material. The metal complex is useful for medical imaging diagnosis and treatment.

  公开了一种化合物的公式：化合物（1）是一种双功能络合剂，可以与金属离子和生物功能材料形成金属络合物。该金属络合物可用于医学成像诊断和治疗。
• Novel harmine derivatives as potent acetylcholinesterase and amyloid beta aggregation dual inhibitors for management of Alzheimer’s disease
  作者：Hongtao Du、Jinzhi Song、Fang Ma、Hongxin Gao、Xinyan Zhao、Renjun Mao、Xiaolong He、Yan Yan

  DOI：10.1080/14756366.2023.2281893

  日期：2023.12.31

  In this study, a series of potential ligands for the treatment of AD were synthesised and characterised as novel harmine derivatives modified at position 9 with benzyl piperazinyl. In vitro studies...

  在本研究中，合成了一系列用于治疗AD的潜在配体，并表征为在9位上用苄基哌嗪基修饰的新型去氢骆驼蓬碱衍生物。体外研究...